

AD \_\_\_\_\_

Award Number: W81XWH-06-1-0179

TITLE: The Role of Vitamin D Stimulation of Mullerian Inhibiting Substance (MIS) in Prostate Cancer Therapy

PRINCIPAL INVESTIGATOR: David Feldman, MD

CONTRACTING ORGANIZATION: Stanford University  
Stanford, CA 94305

REPORT DATE: December 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                          |                            | Form Approved<br>OMB No. 0704-0188                        |                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------|----------------------------|-----------------------------------------------------------|-------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b> |             |                          |                            |                                                           |                                           |
| 1. REPORT DATE (DD-MM-YYYY)<br>01/12/06                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |             | 2. REPORT TYPE<br>Annual |                            | 3. DATES COVERED (From - To)<br>30 Nov 2005 – 29 Nov 2006 |                                           |
| 4. TITLE AND SUBTITLE<br><br>The Role of Vitamin D Stimulation of Mullerian Inhibiting Substance (MIS) in Prostate Cancer Therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |                          |                            | 5a. CONTRACT NUMBER                                       |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 5b. GRANT NUMBER<br>W81XWH-06-1-0179                      |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 5c. PROGRAM ELEMENT NUMBER                                |                                           |
| 6. AUTHOR(S)<br>David Feldman, MD<br><br>E-Mail: <a href="mailto:feldman@cmgm.stanford.edu">feldman@cmgm.stanford.edu</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                          |                            | 5d. PROJECT NUMBER                                        |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 5e. TASK NUMBER                                           |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 5f. WORK UNIT NUMBER                                      |                                           |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>Stanford University<br>Stanford, CA 94305                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |             |                          |                            | 8. PERFORMING ORGANIZATION REPORT NUMBER                  |                                           |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |                          |                            | 10. SPONSOR/MONITOR'S ACRONYM(S)                          |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)                    |                                           |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |                          |                            |                                                           |                                           |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |             |                          |                            |                                                           |                                           |
| 14. ABSTRACT: NO abstract provided                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |                          |                            |                                                           |                                           |
| 15. SUBJECT TERMS<br>No subject terms provided                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |             |                          |                            |                                                           |                                           |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES                                       | 19a. NAME OF RESPONSIBLE PERSON           |
| a. REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | b. ABSTRACT | c. THIS PAGE             |                            |                                                           | USAMRMC                                   |
| U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | U           | U                        | UU                         | 9                                                         | 19b. TELEPHONE NUMBER (include area code) |

## Table of Contents

|                                   | <u>Page</u> |
|-----------------------------------|-------------|
| Introduction.....                 | 2           |
| Body.....                         | 2           |
| Key Research Accomplishments..... | 6           |
| Reportable Outcomes.....          | 6           |
| Conclusion.....                   | 7           |
| References.....                   | 7           |
| Appendices.....                   | N/A         |

## **INTRODUCTION**


We propose that MIS regulation may be an important element contributing to the ability of 1,25-dihydroxyvitamin D<sub>3</sub> (calcitriol) to inhibit the growth and progression of prostate cancer cells. We have shown that calcitriol acts by several pathways to inhibit the growth of prostate cancer cells [1-5]. In the current studies we show that calcitriol also stimulates the expression of MIS in a standard human prostate cancer cell line, LNCaP. We further show that the up-regulation of MIS expression is mediated directly by calcitriol binding to the vitamin d receptor (VDR) and the complex subsequently interacting with a vitamin D regulatory element (VDRE) in the MIS gene promoter.

## **BODY**

We have shown that in the LNCaP prostate cancer cell line, calcitriol treatment upregulates MIS gene expression and MIS protein levels. We identified a 15 bp sequence GGGTGAgcaGGGACA at -395/-381 from the ATG start site in the MIS promoter (Fig.1). The MIS promoter also contains response elements for GATA-4, SOX9 and SF-1.

**Fig. 1. A putative vitamin D response element (VDRE) is present in the MIS promoter.** Panel A:

The human MIS gene is on chromosome 19 and is located between the SF3A2 gene and the JSRP1 gene. The MIS transcriptional start site is located only 748 bp downstream of the termination codon of the SF3A2 gene. Arrows indicate direction of transcription. Panel B: Using *in silico* analysis, we identified a putative VDRE in the MIS promoter. The VDRE is located at




nucleotides -381 to -396 relative to the ATG translation start site. The location of transcription factor binding sites for SF-1, SOX9 and GATA-4 that regulate MIS promoter activity are also shown.

We cloned a 680 bp fragment (-657 to +23) of the MIS promoter containing the putative VDRE into a luciferase reporter vector (Fig. 2). In transactivation assays in HeLa cells, we demonstrated that the MIS promoter activity was upregulated by calcitriol.



**Fig. 2. Transactivation of the MIS promoter by 1,25-(OH)<sub>2</sub>D<sub>3</sub>**

**in HeLa cells.** Panel A: Illustration of the MIS promoter construct. Panel B: HeLa cells were transfected with a VDR expression vector and the MIS promoter luciferase reporter construct. Cells were treated with vehicle or 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 24 hr. Luciferase activity was measured using the dual luciferase assay. Values represent mean  $\pm$ SD of triplicate transfections.





Co-expression of VDR with steroidogenic factor 1 (SF-1), a key regulator of MIS, increased MIS promoter basal activity that was further stimulated by calcitriol treatment (Fig. 3).

**Fig. 3. Steroidogenic factor 1 (SF-1) and**

**VDR cooperate to increase MIS promoter activity in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub>.** Panel A:


MIS promoter-luciferase construct. Panel B: Transactivation assays in HeLa cells transfected with vector alone (pSG5), VDR alone, VDR and SF-1 or VDR and SF-1 with a deletion of the ligand binding domain (SF-1 $\Delta$ LBD) and the MIS promoter-luciferase construct. Cells were



treated with vehicle or 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 24 hr and luciferase activity measured. Values represent mean ±SD of triplicate transfections.

We created a single point mutation in the putative VDRE or deleted of the entire 15 base sequence. Both mutations resulted in the loss of calcitriol-induced transactivation (Fig. 4).


**Fig. 4. Mutations in the MIS VDRE reduce 1,25-(OH)<sub>2</sub>D<sub>3</sub> responsiveness.** Panel A: A single G to T point mutation in the 3-prime hexamer of the VDRE (MISpro mut-1) and a 15 bp deletion of the entire VDRE (MISpro ΔVDRE) were created in the MIS promoter. Panel B: Transactivation assays in HeLa cells transfected with VDR and SF-1 expression vectors and the MIS promoter luciferase constructs. Cells were treated with vehicle or 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 24 hr and luciferase activity measured. Values represent mean ±SD of triplicate transfections.



In gel shift assays, the VDR bound the MIS VDRE and the binding was increased by calcitriol (Fig. 5).

**Fig. 5. The VDR binds to the MIS VDRE *in***

*vitro*. [<sup>32</sup>P]-labeled MIS and osteopontin (OP) VDREs were incubated with COS-7 extracts transfected with vector alone (pSG5), WT VDR, or VDR E420K a coactivator binding defective mutant. Samples were incubated with and without 10 nM 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 30 min at ambient temperature. The samples were then



electrophoresed on 5% polyacrylamide gels in 0.5X Tris-borate buffer for 170 min at 70 volts. Bands were visualized by autoradiography. 1,25D, 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

We cloned the 15 bp MIS VDRE sequence into an enhancerless heterologous promoter in pGL3promoter vector. The 15 bp MIS VDRE was able to confer vitamin D responsiveness to the heterologous promoter demonstrating that this nucleotide sequenced is a bona fide VDRE (Fig. 6).

**Fig. 6. The MIS VDRE confers 1,25-(OH)<sub>2</sub>D<sub>3</sub> responsiveness**

**to a heterologous promoter.** Panel A: The 15 bp MIS VDRE

was cloned into pGL3-promoter containing an SV40 promoter.


Panel B: Transactivation assays in HeLa cells transfected with a

VDR expression vector and the MIS VDRE luciferase reporter

construct. Cells were treated with vehicle or 1,25-(OH)<sub>2</sub>D<sub>3</sub> for

24 hr and luciferase activity measured. Values represent mean

±SD of triplicate transfections.



In Fig. 7, we demonstrate *in vivo* that the VDR binds to the MIS promoter in LNCaP cells using chromatin immunoprecipitation.

**Fig. 7. The VDR interacts with the MIS VDRE in intact LNCaP**

**human prostate cancer cells.** LNCaP cells were treated with and


without 10 nM 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 6 hr at 37°C. The cells were then fixed

with 1% formaldehyde for 10 min at ambient temperature. The samples

were washed with phosphate-buffered saline and then analyzed by

chromatin immunoprecipitation (ChIP) assays. ChIP assays were

performed with VDR and control IgG antibodies. Input represents DNA extracted prior to ChIP assay.



We have demonstrated for the first time that the MIS gene is a new target of calcitriol action. The MIS promoter contains a functional VDRE that binds the VDR and MIS is upregulated by calcitriol in prostate cancer cells. We are currently determining whether upregulation of MIS contributes to the anti-proliferative/pro-apoptotic actions of calcitriol in prostate cancer. We have recently obtained purified MIS from Dr. Donahoe's lab that we will use to test the combined effects of calcitriol and MIS on prostate cancer cell growth.

### **KEY RESEARCH ACCOMPLISHMENTS**

- Demonstrated that MIS is produced by human prostate cancer cells
- Proved that MIS is a target of calcitriol
- Identified a VDRE in the MIS promoter
- Confirmed in vivo in cells that VDR acting via the VDRE up-regulates MIS

### **REPORTABLE OUTCOMES**

P.J. Malloy and D. Feldman. Mullerian Inhibitory Substance (MIS) is upregulated by 1,25-dihydroxyvitamin D<sub>3</sub> in LNCaP prostate cancer cells via a direct interaction of the vitamin D receptor with a vitamin D regulatory element in the MIS promoter.

Endocrine Society 88<sup>th</sup> Annual Meeting, Boston MA June 24-27, 2006.poster 3-55.

H.D. Mason, L. Hanna, S. Rice, H. Brain, P.J. Malloy, D. Feldman, M Brincat, R. Galea, S.A. Whitehead, and L.J. Pellat, Role of Anti-Mullerian Hormone (AMH) in anovulatory polycystic ovarian syndrome. Endocrine Society 88<sup>th</sup> Annual Meeting, Boston MA June 24-27, 2006. Oral presentation OR38-3.



## **CONCLUSIONS**

These studies add a new dimension to calcitriol action by adding the regulation of a new and previously unknown protein to the list of regulated substances by calcitriol. Since MIS is an important protein that regulates organ development and is currently in studies as an anti-cancer agent, this finding suggests that MIS may be useful in prostate cancer therapy and that calcitriol's regulation of MIS may contribute to its anti-cancer activity. Future studies will examine whether adding MIS to calcitriol will enhance the action of both molecules as anti-cancer agents.

## **REFERENCES**

1. J. Moreno, A.V. Krishnan, S. Swami, L. Nonn, D.M. Peehl, and D. Feldman, Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. *Cancer Res.* 65:7917-25, 2005.
2. J. Moreno, A. V. Krishnan and D. Feldman, Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. *J. Steroid Biochem. Mol. Biol.* 97:31-36, 2005.
3. L. Nonn, L. Peng, D. Feldman, D.M. Peehl, Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via MAP Kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D. *Cancer Res.* 66:4516-4524, 2006.
4. J. Moreno, A.V. Krishnan, D.M. Peehl, D. Feldman, Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. *Anticancer Res* 26: (4A) 2525-30, 2006.
5. A.V. Krishnan, J. Moreno, L. Nonn, P. Malloy, S. Swami , L. Peng, D. M. Peehl and D. Feldman, Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. *J Steroid Biochem. Mol. Biol.* 103:694-702, 2007